U.S. markets closed
  • S&P Futures

    3,830.50
    +21.25 (+0.56%)
     
  • Dow Futures

    31,044.00
    +132.00 (+0.43%)
     
  • Nasdaq Futures

    12,991.50
    +80.50 (+0.62%)
     
  • Russell 2000 Futures

    2,224.00
    +24.80 (+1.13%)
     
  • Crude Oil

    62.38
    +0.88 (+1.43%)
     
  • Gold

    1,734.30
    +5.50 (+0.32%)
     
  • Silver

    26.76
    +0.32 (+1.21%)
     
  • EUR/USD

    1.2092
    -0.0094 (-0.77%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3972
    -0.0041 (-0.29%)
     
  • USD/JPY

    106.4850
    +0.2550 (+0.24%)
     
  • BTC-USD

    45,480.79
    -1,083.12 (-2.33%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.29 (-3.99%)
     

FDA Approves Regeneron/Sanofi's Libtayo For Front-Line Lung Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA approved expanded use of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi’s SA (NASDAQ: SNY) immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced lung cancer, marking the third approval for Libtayo and second this month.

  • The drug is now cleared for adults with non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression of at least 50%, a protein that’s correlated with response to immunotherapy, and have metastatic or locally advanced tumors that can’t be removed by surgery and must not have EGFR, ALK or ROS1 aberrations.

  • Just two weeks ago, Libtayo was approved for advanced basal cell carcinoma, the most common skin cancer type in the U.S.

  • Simultaneously, the agency also approved Agilent Technologies’ (NYSE: A) PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify NSCLC patients eligible for cemiplimab treatment on a PD-L1 expression of at least 50%.

  • Libtayo was approved in 2018 for metastatic cutaneous squamous cell carcinoma, a common form of skin cancer.

  • Price Action: SNY, REGN and A closed 0.6%, 2.08% and 2.7% lower at $46.36, $460.58 and $123.50, respectively on Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.